Results 101 to 110 of about 76,618 (225)

BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single [PDF]

, 2010
Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP.
Campanilho-Marques, R., Canhao, Helena, Costa, M., Fonseca, João Eurico, Martins, F., Pereira da Silva, José A., Polido-Pereira, J., Ramos, F., Rodrigues, A., Saavedra, M. J.   +9 more
core  

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source

SCORTEN and Novel Prognostic Markers in Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and Meta‐Analysis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe skin reaction with high mortality, most often triggered by medications. Early identification of patients at risk is essential for guiding treatment. The SCORTEN score, comprising seven clinical and laboratory variables, is widely used to predict mortality but may ...
Zhao Feng Liu, Howard Yang, Lawrence Lin, Ash Tyagi, Amy Sylivris, Adithya Shastry, Nidhin Sunil Kuruvilla, Douglas Gin, Christopher Y. Chew   +8 more
wiley   +1 more source

TNF‐α partially modulates the endothelial dysfunction during the acute phase of Trypanosoma cruzi infection

British Journal of Pharmacology, EarlyView.
Background and Purpose Whereas the effects of Trypanosoma cruzi (T. cruzi) infection are well‐characterised in the heart, its impact on the vasculature has received little attention. In this study, we investigated the effects of acute and chronic T. cruzi infection on vascular responsiveness and the underlying mechanisms.
Thales M. H. Dourado, Wanessa M. C. Awata, Gustavo F. Pimenta, Barbara M. Marchetti, Maiara V. Providello, Sérgio De Albuquerque, Carlos R. Tirapelli   +6 more
wiley   +1 more source

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Mediators of Inflammation, 2019
In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis ...
Iwao Seki, Miwa Takai-Imamura, Tomomi Kohara-Tanaka, Satoshi Shirae, Minoru Sasano, Hiroaki Matsuno, Hiroyuki Aono   +6 more
doaj   +1 more source

Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis

مجلة كلية الطب, 2015
Background: Since the introduction of tumour necrosis factor-alpha (TNF-α) inhibitors including etanercept, their efficacy and safety in treatment of rheumatoid arthritis (RA) have been studied in many randomized controlled clinical trials. However, data
Nizar A. Jassim
doaj   +1 more source

Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis:A Brief Review [PDF]

, 2019
Rheumatoid arthritis is a chronic autoimmune disease that is a major public health challenge. The disease is characterised by inflammation of synovial joints and cartilage erosion, which lead to chronic pain, poor life quality and, in some cases ...
Chaplain, Mark A. J., Eftimie, Raluca, Macfarlane, Fiona R.   +2 more
core   +4 more sources

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana, George Macfarlane, Elizabeth Mairenn Garden, Liam Lee, Gabija Klyvyte, Lavandan Jegatheeswaran, Rebecca Davies, Carl Philpott   +7 more
wiley   +1 more source

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

BMC Musculoskeletal Disorders, 2004
Background Variability in dosing and costs of biologics among patients with rheumatoid arthritis (RA) is of interest to healthcare descision-makers.
Smith Daniel, Gilbert Thomas D, Ollendorf Daniel A   +2 more
doaj  

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis

Practical Laboratory Medicine, 2019
Objective: Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was
Nicole Yang, Jie Huang, Michelle Frits, Christine Iannaccone, Michael E. Weinblatt, Nader Rifai, Nancy Shadick, Gary Bradwin, Katherine P. Liao   +8 more
doaj   +1 more source